Titre : Facteur de stimulation des colonies de granulocytes et de macrophages

Facteur de stimulation des colonies de granulocytes et de macrophages : Questions médicales fréquentes

Termes MeSH sélectionnés :

Reproducibility of Results
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Facteur de stimulation des colonies de granulocytes et de macrophages : Questions médicales les plus fréquentes", "headline": "Facteur de stimulation des colonies de granulocytes et de macrophages : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Facteur de stimulation des colonies de granulocytes et de macrophages : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-15", "dateModified": "2025-05-10", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Facteur de stimulation des colonies de granulocytes et de macrophages" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Facteurs de stimulation des colonies", "url": "https://questionsmedicales.fr/mesh/D003115", "about": { "@type": "MedicalCondition", "name": "Facteurs de stimulation des colonies", "code": { "@type": "MedicalCode", "code": "D003115", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.410.240" } } }, "about": { "@type": "MedicalCondition", "name": "Facteur de stimulation des colonies de granulocytes et de macrophages", "alternateName": "Granulocyte-Macrophage Colony-Stimulating Factor", "code": { "@type": "MedicalCode", "code": "D016178", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sameh Basta", "url": "https://questionsmedicales.fr/author/Sameh%20Basta", "affiliation": { "@type": "Organization", "name": "Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada. Electronic address: bastas@queensu.ca." } }, { "@type": "Person", "name": "Katrina Gee", "url": "https://questionsmedicales.fr/author/Katrina%20Gee", "affiliation": { "@type": "Organization", "name": "Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada. Electronic address: kgee@queensu.ca." } }, { "@type": "Person", "name": "Evan Trus", "url": "https://questionsmedicales.fr/author/Evan%20Trus", "affiliation": { "@type": "Organization", "name": "Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada." } }, { "@type": "Person", "name": "Maria Petrina", "url": "https://questionsmedicales.fr/author/Maria%20Petrina", "affiliation": { "@type": "Organization", "name": "Department of Biomedical and Molecular Sciences, Queen's University, Botterell Hall, Kingston, ON, K7L 3N6, Canada." } }, { "@type": "Person", "name": "Torki Alothaimeen", "url": "https://questionsmedicales.fr/author/Torki%20Alothaimeen", "affiliation": { "@type": "Organization", "name": "Department of Biomedical and Molecular Sciences, Queen's University, Botterell Hall, Kingston, ON, K7L 3N6, Canada." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Evidence of validity and reliability of Jumpo 2 and MyJump 2 for estimating vertical jump variables.", "datePublished": "2023-01-25", "url": "https://questionsmedicales.fr/article/36718456", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7717/peerj.14558" } }, { "@type": "ScholarlyArticle", "name": "Uric acid levels and their association with vascular dementia and Parkinson's disease dementia: a meta-analysis.", "datePublished": "2023-01-24", "url": "https://questionsmedicales.fr/article/36690824", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10072-023-06620-3" } }, { "@type": "ScholarlyArticle", "name": "Efficacy of Small versus Large-Bore Chest Drain in Pleural Infection: A Systematic Review and Meta-Analysis.", "datePublished": "2023-01-24", "url": "https://questionsmedicales.fr/article/36693327", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000529027" } }, { "@type": "ScholarlyArticle", "name": "ProteomicsML: An Online Platform for Community-Curated Data sets and Tutorials for Machine Learning in Proteomics.", "datePublished": "2023-01-24", "url": "https://questionsmedicales.fr/article/36693629", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acs.jproteome.2c00629" } }, { "@type": "ScholarlyArticle", "name": "Within-subject reliability of concurrent TMS-fMRI during a single session.", "datePublished": "2023-01-24", "url": "https://questionsmedicales.fr/article/36694109", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/psyp.14252" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Cytokines", "item": "https://questionsmedicales.fr/mesh/D016207" }, { "@type": "ListItem", "position": 5, "name": "Facteurs de croissance hématopoïétique", "item": "https://questionsmedicales.fr/mesh/D016298" }, { "@type": "ListItem", "position": 6, "name": "Facteurs de stimulation des colonies", "item": "https://questionsmedicales.fr/mesh/D003115" }, { "@type": "ListItem", "position": 7, "name": "Facteur de stimulation des colonies de granulocytes et de macrophages", "item": "https://questionsmedicales.fr/mesh/D016178" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Facteur de stimulation des colonies de granulocytes et de macrophages - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Facteur de stimulation des colonies de granulocytes et de macrophages", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Facteur de stimulation des colonies de granulocytes et de macrophages", "description": "Comment diagnostiquer une carence en GM-CSF ?\nQuels tests sont utilisés pour évaluer le GM-CSF ?\nQuels symptômes indiquent un besoin de GM-CSF ?\nLe GM-CSF est-il mesurable dans le sang ?\nQuels signes cliniques sont associés à un déficit en GM-CSF ?", "url": "https://questionsmedicales.fr/mesh/D016178?mesh_terms=Reproducibility+of+Results&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Facteur de stimulation des colonies de granulocytes et de macrophages", "description": "Quels symptômes sont liés à un excès de GM-CSF ?\nComment le GM-CSF affecte-t-il le système immunitaire ?\nLe GM-CSF peut-il causer des effets secondaires ?\nQuels signes indiquent une réaction allergique au GM-CSF ?\nLe GM-CSF influence-t-il la fatigue ?", "url": "https://questionsmedicales.fr/mesh/D016178?mesh_terms=Reproducibility+of+Results&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Facteur de stimulation des colonies de granulocytes et de macrophages", "description": "Comment prévenir les carences en GM-CSF ?\nLe GM-CSF peut-il être administré préventivement ?\nQuelles mesures de prévention sont recommandées ?\nLe GM-CSF aide-t-il à la prévention des infections ?\nQuels conseils pour les patients sous GM-CSF ?", "url": "https://questionsmedicales.fr/mesh/D016178?mesh_terms=Reproducibility+of+Results&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Facteur de stimulation des colonies de granulocytes et de macrophages", "description": "Comment le GM-CSF est-il administré ?\nQuels sont les usages thérapeutiques du GM-CSF ?\nLe GM-CSF est-il utilisé en oncologie ?\nQuels médicaments contiennent du GM-CSF ?\nLe GM-CSF peut-il être utilisé en cas d'infection ?", "url": "https://questionsmedicales.fr/mesh/D016178?mesh_terms=Reproducibility+of+Results&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Facteur de stimulation des colonies de granulocytes et de macrophages", "description": "Quelles complications peuvent survenir avec le GM-CSF ?\nLe GM-CSF peut-il provoquer des effets indésirables graves ?\nComment gérer les effets secondaires du GM-CSF ?\nLe GM-CSF peut-il aggraver certaines conditions ?\nQuels signes d'alerte doivent être surveillés ?", "url": "https://questionsmedicales.fr/mesh/D016178?mesh_terms=Reproducibility+of+Results&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Facteur de stimulation des colonies de granulocytes et de macrophages", "description": "Quels facteurs augmentent le besoin en GM-CSF ?\nLes personnes âgées ont-elles besoin de plus de GM-CSF ?\nLes maladies auto-immunes influencent-elles le GM-CSF ?\nLe stress affecte-t-il le niveau de GM-CSF ?\nLes infections chroniques augmentent-elles le besoin en GM-CSF ?", "url": "https://questionsmedicales.fr/mesh/D016178?mesh_terms=Reproducibility+of+Results&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une carence en GM-CSF ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins mesurant les niveaux de GM-CSF et l'évaluation des cellules immunitaires sont nécessaires." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer le GM-CSF ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les dosages immunologiques et les tests de culture cellulaire sont couramment utilisés." } }, { "@type": "Question", "name": "Quels symptômes indiquent un besoin de GM-CSF ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une immunodéficience, infections fréquentes et anémie peuvent indiquer un besoin de GM-CSF." } }, { "@type": "Question", "name": "Le GM-CSF est-il mesurable dans le sang ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le GM-CSF peut être mesuré dans le sérum par des techniques de dosage spécifiques." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à un déficit en GM-CSF ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des infections récurrentes et une mauvaise cicatrisation des plaies." } }, { "@type": "Question", "name": "Quels symptômes sont liés à un excès de GM-CSF ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Un excès peut provoquer des symptômes inflammatoires, comme de la fièvre et des douleurs." } }, { "@type": "Question", "name": "Comment le GM-CSF affecte-t-il le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Il stimule la production de cellules immunitaires, renforçant ainsi la réponse immunitaire." } }, { "@type": "Question", "name": "Le GM-CSF peut-il causer des effets secondaires ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires comme des douleurs musculaires et des réactions au site d'injection peuvent survenir." } }, { "@type": "Question", "name": "Quels signes indiquent une réaction allergique au GM-CSF ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent indiquer une allergie." } }, { "@type": "Question", "name": "Le GM-CSF influence-t-il la fatigue ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Il peut réduire la fatigue en améliorant la fonction immunitaire et la production de globules blancs." } }, { "@type": "Question", "name": "Comment prévenir les carences en GM-CSF ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un suivi médical régulier peuvent aider à prévenir les carences." } }, { "@type": "Question", "name": "Le GM-CSF peut-il être administré préventivement ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut être administré pour prévenir les infections chez les patients à risque." } }, { "@type": "Question", "name": "Quelles mesures de prévention sont recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des vaccinations et une bonne hygiène sont recommandées pour prévenir les infections." } }, { "@type": "Question", "name": "Le GM-CSF aide-t-il à la prévention des infections ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il renforce le système immunitaire, aidant à prévenir les infections." } }, { "@type": "Question", "name": "Quels conseils pour les patients sous GM-CSF ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les patients doivent éviter les foules et se laver fréquemment les mains pour prévenir les infections." } }, { "@type": "Question", "name": "Comment le GM-CSF est-il administré ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il est généralement administré par injection sous-cutanée ou intraveineuse." } }, { "@type": "Question", "name": "Quels sont les usages thérapeutiques du GM-CSF ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Il est utilisé pour traiter les neutropénies et améliorer la récupération après chimiothérapie." } }, { "@type": "Question", "name": "Le GM-CSF est-il utilisé en oncologie ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est utilisé pour stimuler la production de globules blancs chez les patients cancéreux." } }, { "@type": "Question", "name": "Quels médicaments contiennent du GM-CSF ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme le sargramostim contiennent du GM-CSF pour traiter certaines conditions." } }, { "@type": "Question", "name": "Le GM-CSF peut-il être utilisé en cas d'infection ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Il peut être utilisé pour renforcer la réponse immunitaire lors d'infections sévères." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le GM-CSF ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des réactions allergiques, des douleurs osseuses et des infections." } }, { "@type": "Question", "name": "Le GM-CSF peut-il provoquer des effets indésirables graves ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets indésirables graves comme des troubles respiratoires peuvent survenir." } }, { "@type": "Question", "name": "Comment gérer les effets secondaires du GM-CSF ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut l'ajustement de la dose et le traitement des symptômes associés." } }, { "@type": "Question", "name": "Le GM-CSF peut-il aggraver certaines conditions ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut aggraver des maladies auto-immunes en stimulant le système immunitaire." } }, { "@type": "Question", "name": "Quels signes d'alerte doivent être surveillés ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Surveillez des signes comme des douleurs thoraciques, des éruptions cutanées ou des fièvres élevées." } }, { "@type": "Question", "name": "Quels facteurs augmentent le besoin en GM-CSF ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements de chimiothérapie, les infections chroniques et les maladies hématologiques augmentent le besoin." } }, { "@type": "Question", "name": "Les personnes âgées ont-elles besoin de plus de GM-CSF ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent avoir un besoin accru en raison d'une immunité diminuée." } }, { "@type": "Question", "name": "Les maladies auto-immunes influencent-elles le GM-CSF ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent augmenter la production de GM-CSF en réponse à l'inflammation." } }, { "@type": "Question", "name": "Le stress affecte-t-il le niveau de GM-CSF ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut influencer la production de cytokines, y compris le GM-CSF." } }, { "@type": "Question", "name": "Les infections chroniques augmentent-elles le besoin en GM-CSF ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent nécessiter une stimulation accrue de la production de globules blancs." } } ] } ] }

Sources (10000 au total)

Evidence of validity and reliability of Jumpo 2 and MyJump 2 for estimating vertical jump variables.

We investigated the concurrent validity and test-retest reliability of the Jumpo 2 and MyJump 2 apps for estimating jump height, and the mean values of force, velocity, and power produced during count... Physically active university aged men (... Both apps provided a reliable estimate of jump height and the mean values of force, velocity, and power. Furthermore, estimates of jump height for CMJ and SJ and the mean force of the CMJ were valid. ... Therefore, Jumpo 2 and MyJump 2 both provide a valid measure of jump height, but the remaining variables provided by these apps must be viewed with caution since the validity of force depends on jump ...

Uric acid levels and their association with vascular dementia and Parkinson's disease dementia: a meta-analysis.

To explore the association between uric acid (UA) levels and vascular dementia (VaD) and Parkinson's disease dementia (PDD), a meta-analysis was conducted.... The relevant studies were identified by searching PubMed, Embase, Web of Science, and Cochrane Collaboration Database up to May 2022. Pooled analysis, sensitivity analysis, and publication bias examin... Twelve studies with a total of 2097 subjects were included. The pooled analysis showed that UA levels were not associated with VaD (WMD = - 10.99 μmol/L, 95% CI (- 48.05, 26.07), P = 0.561) but were a... UA levels are associated with PDD but not with VaD. This study will help to strengthen our knowledge of the pathophysiologies of VaD and PDD, and promote the development of prevention and treatment st...

Efficacy of Small versus Large-Bore Chest Drain in Pleural Infection: A Systematic Review and Meta-Analysis.

Pleural infection represents a significant clinical challenge worldwide. Although prompt drainage of pleural fluid is thought to play a key role in pleural infection management, the optimal size of in... The aim of this systematic review and meta-analysis was to summarize data on efficacy and complications of small-bore drain (SBD), defined as ≤14F, in comparison to large-bore drain (LBD) in patients ... We searched MEDLINE and Embase for all studies reporting outcomes of interest published up to October 2021. Two authors reviewed selected full text to identify studies according to predefined eligibil... Twelve original studies were included for qualitative analysis and 7 of these for quantitative analysis. The surgical referral rate of SBD and LBD were, respectively, 0.16 (95% confidence interval [CI... This systematic review and meta-analysis provide the first synthesis of data on performance of SBD and LBD in management of pleural infection, and, overall, clinical outcomes and complications did not...

The Cognitive and Behavioural Responses to Symptoms Questionnaire (CBRQ): Development, reliability and validity across several long-term conditions.

Cognitive and behavioural responses to symptoms can worsen or maintain the severity of symptoms across long-term conditions (LTCs). Although the Cognitive and Behavioural Responses Questionnaire (CBRQ... Psychometric validation study.... Confirmatory factor analysis (CFA) tested the factor structure of the CBRQ in two datasets from the CBRQ's original development; (chronic fatigue syndrome, N = 230; and multiple sclerosis, N = 221) an... CFA revealed that a 7-or 8-factor structure had generally appropriate fit supporting the originally proposed 7 factors (Fear avoidance, Damage beliefs, Catastrophising, Embarrassment avoidance, Sympto... The CBRQ and the shortened version were shown to be reliable and valid at assessing a range of cognitive and behavioural responses to symptoms, highlighting the multi-symptom, transdiagnostic properti...

Non-hospital healthcare center's preparedness assessment toolbar for providing basic emergency care: a sequential exploratory mixed-method study.

Basic emergency management in urban and rural areas is a critical challenge, which can affect the pre-hospital mortality rate. Therefore, Non-hospital Healthcare Center (NHHC) must be prepared to mana... This study was designed based on a sequential exploratory mixed- method in two phases, in each of which there are three steps. In the phase I, the literature systematic review and qualitative methods ... In the phase I, primary version of the toolbar containing 134 items related to assessing the preparedness of NHHCs was generated. In the phase II, item reduction was applied and the final version of t... This study provided a standard and valid toolbar that can be used to assess the preparedness of NHHCs to deliver initial emergency care....

AI-based dimensional neuroimaging system for characterizing heterogeneity in brain structure and function in major depressive disorder: COORDINATE-MDD consortium design and rationale.

Efforts to develop neuroimaging-based biomarkers in major depressive disorder (MDD), at the individual level, have been limited to date. As diagnostic criteria are currently symptom-based, MDD is conc... We describe a consortium to quantify neuroanatomical and neurofunctional heterogeneity via the dimensions of novel multivariate coordinate system (COORDINATE-MDD). Utilizing imaging harmonization and ... We are applying an iterative process by defining the neural dimensions that characterise deeply phenotyped samples and then testing the dimensions in novel samples to assess specificity and reliabilit... We describe the consortium, imaging protocols and analytics using preliminary results. Our findings thus far demonstrate how datasets across many sites can be harmonized and constructively pooled to e...

Factor structure and internal consistency of the parent patient activation measure (P-PAM) in parents of children with ADHD in norwegian paediatric mental health.

This study aimed to explore the internal consistency and factor validity of the 13-item self-report questionnaire Parent-Patient Activation Measure (P-PAM) in a sample of parents of children with Atte... In a cross-sectional study, 239 parents were recruited from four outpatient clinics of the Child and Adolescent Mental Health Services and completed the P-PAM along with demographic variables. The fac... The fit indices suggest an acceptable two-factor model of P-PAM and show high internal consistency and reliability for both factors, indicating that the scale measures two concepts.... Our findings provide evidence for an acceptable factor structure and a high reliability of P-PAM as a measure of parent activation, suggesting that the theoretical factors reflect the construct of par...

The development of a Brief Working Alliance Inventory for clients and therapists using multilevel factor analysis and item response theory in the United States and China.

This study aimed to investigate the multilevel factor structure of the therapist and client versions of the 12-item Working Alliance Inventory-Short Revised (WAI; Hatcher & Gillaspy, 2006) in the Unit...